Karlijn J G Schulkes1, Cindy Nguyen2, Frederiek van den Bos3, Leontine J R van Elden4, Marije E Hamaker5. 1. Department of Internal Medicine, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands. kschulkes@diakhuis.nl. 2. Department of Internal Medicine, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands. 3. Department of Internal Medicine, Haga Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands. 4. Department of Pulmonology, Diakonessenhuis Utrecht, Utrecht, The Netherlands. 5. Department of Geriatric Medicine, Diakonessenhuis Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: Lung cancer is predominantly a disease of the elderly: half of all newly diagnosed patients are over 70 years old. Older patients and those with comorbidities are underrepresented in clinical trials; scientific communities have addressed this issue since the end of the 20th century. We set out to determine the characteristics of the selection of patients in lung cancer trials that are currently recruiting. METHODS: We searched The United States National Institutes of Health (NIH) clinical trial registry ( www.clinicaltrials.gov ) on April 23, 2015 for currently recruiting phase I, II, or III clinical trials in lung cancer. Trial characteristics and study objectives were extracted from the registry website. RESULTS: Of the 419 trails selected in this overview, 88 % explicitly or implicitly excluded elderly patients. Patients were excluded based on stringent organ selection in 76 % of the trials, based on performance status (57 %) and based on age (13 %). The median number of placed restrictions per trial was seven. In the 2 % of the trials that were exclusively designed for elderly patients only fit patients were included. CONCLUSION: In this overview of current lung cancer trials registered in the NIH clinical trial registry, we found that elderly patients and those with comorbidities are often excluded from participation in clinical trials. Therefore, it is difficult for physicians and their frail patients to properly evaluate the efficacy and safety of current treatment options. More research that includes the elderly and those with comorbidities is urgently needed.
BACKGROUND:Lung cancer is predominantly a disease of the elderly: half of all newly diagnosed patients are over 70 years old. Older patients and those with comorbidities are underrepresented in clinical trials; scientific communities have addressed this issue since the end of the 20th century. We set out to determine the characteristics of the selection of patients in lung cancer trials that are currently recruiting. METHODS: We searched The United States National Institutes of Health (NIH) clinical trial registry ( www.clinicaltrials.gov ) on April 23, 2015 for currently recruiting phase I, II, or III clinical trials in lung cancer. Trial characteristics and study objectives were extracted from the registry website. RESULTS: Of the 419 trails selected in this overview, 88 % explicitly or implicitly excluded elderly patients. Patients were excluded based on stringent organ selection in 76 % of the trials, based on performance status (57 %) and based on age (13 %). The median number of placed restrictions per trial was seven. In the 2 % of the trials that were exclusively designed for elderly patients only fit patients were included. CONCLUSION: In this overview of current lung cancer trials registered in the NIH clinical trial registry, we found that elderly patients and those with comorbidities are often excluded from participation in clinical trials. Therefore, it is difficult for physicians and their frail patients to properly evaluate the efficacy and safety of current treatment options. More research that includes the elderly and those with comorbidities is urgently needed.
Authors: Elisabeth A Kastelijn; Sherif Y El Sharouni; Frederik N Hofman; Bart P Van Putte; Evelyn M Monninkhof; Marco Van Vulpen; Franz M N H Schramel Journal: Anticancer Res Date: 2015-10 Impact factor: 2.480
Authors: Karlijn J G Schulkes; Carin A M Pouw; Elisabeth J M Driessen; Leontine J R van Elden; Frederiek van den Bos; Maryska L G Janssen-Heijnen; Jan-Willem J Lammers; Marije E Hamaker Journal: Lung Date: 2017-06-19 Impact factor: 2.584
Authors: Florence Canouï-Poitrine; Astrid Lièvre; Florent Dayde; Daniel Lopez-Trabada-Ataz; Isabelle Baumgaertner; Olivier Dubreuil; Francesco Brunetti; Romain Coriat; Karin Maley; Simon Pernot; Christophe Tournigand; Meoin Hagege; Thomas Aparicio; Elena Paillaud; Sylvie Bastuji-Garin Journal: Oncologist Date: 2019-07-19
Authors: Mitchell S von Itzstein; Amrit S Gonugunta; Helen G Mayo; John D Minna; David E Gerber Journal: Cancer J Date: 2020 Nov/Dec Impact factor: 2.074
Authors: Karlijn J G Schulkes; Esteban T D Souwer; Marije E Hamaker; Henk Codrington; Simone van der Sar-van der Brugge; Jan-Willem J Lammers; Johanneke E A Portielje; Leontine J R van Elden; Frederiek van den Bos Journal: Lung Date: 2017-03-09 Impact factor: 2.584
Authors: Frances B Maguire; Cyllene R Morris; Arti Parikh-Patel; Rosemary D Cress; Theresa H M Keegan; Chin-Shang Li; Patrick S Lin; Kenneth W Kizer Journal: PLoS One Date: 2019-02-22 Impact factor: 3.240
Authors: Jon Cacicedo; Francisco Casquero; Arturo Navarro; Lorea Martinez-Indart; Olga Del Hoyo; Andere Frías; Roberto Ortiz de Zarate; David Büchser; Alfonso Gómez-Iturriaga; Iñigo San Miguel; Fernan Suarez; Adrian Barcena; Jose Luis López-Guerra Journal: BJR Open Date: 2022-06-13